EU · Phase III · IgA nephropathy
EU Phase III IgA nephropathy trials: sites, PIs, CROs and competition
Assistance Publique Hôpitaux de Paris contributes to eight of 12 Phase III IgA nephropathy studies, followed by Hospital Universitari Vall d’Hebron with seven. Loreto Gesualdo and Vladimír Tesař each contribute to seven studies. The EU network spans 302 distinct listed sites and 334 named investigators across 23 Member States.
Top 5 sites · 12 Phase III IgA nephropathy studies
AP-HP leads with eight studies, followed by Vall d’Hebron with seven
General University Hospital in Prague contributes to six studies. Nantes University Hospital and Hospital 12 de Octubre each contribute to five.
Trial participation describes documented Phase III IgA nephropathy experience, not recruitment performance or current capacity.
Top 5 investigators · 12 Phase III IgA nephropathy studies
Loreto Gesualdo and Vladimír Tesař each contribute to seven studies
Michał Nowicki and Julia Weinmann-Menke follow with six study participations each. Kathleen Claes contributes to five.
Obvious case and accent variants are normalized when counting investigators.
Top 5 CROs · Documented Phase III IgA involvement
IQVIA and PPD / Thermo Fisher each support five studies
Parexel and Syneos Health each appear across three studies, while ICON appears across two.
Clearly related legal entities are consolidated into CRO groups. Counts indicate documented study involvement, not an assessment of CRO quality or sole-vendor responsibility.
Planned sample size · Phase III IgA nephropathy
Five programs plan more than 500 participants
The adult ravulizumab study has the largest planned total at 573 participants, followed by PREVAIL at 561. The median across all 12 Phase III studies is 416 planned participants.
Planned totals combine the current CTIS non-EU subject count with Member State recruitment allocations. They are targets, not confirmed enrollment.
Current competition · Authorised and recruiting
Six Phase III IgA studies are recruiting in at least one EU country
PREVAIL and the mezagitamab Phase III program each recruit in 11 EU countries. PREVAIL lists 88 recruiting EU sites, while mezagitamab lists 44.
| Trial | Planned sample size | Recruiting EU countries | Recruiting EU sites |
|---|---|---|---|
| PREVAIL | 561 | 11 | 88 |
| Mezagitamab Phase III | 347 | 11 | 44 |
| ALIGN | 404 | 3 | 9 |
| Zigakibart extension | 220 | 2 | 10 |
| SABINE | 120 | 1 | 8 |
| Pediatric ravulizumab Phase III | 18 | 1 | 3 |
Current competition includes studies with CTIS status Authorised and at least one EU Member State marked Recruiting on 20 September 2026.